School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
Department of Neurosurgery, New York University Grossman School of Medicine, New York City, NYC, USA.
Neurosurg Rev. 2024 Sep 5;47(1):541. doi: 10.1007/s10143-024-02783-5.
Despite unprecedented survival in patients with glioblastoma (GB), the aggressive primary brain cancer remains largely incurable and its mechanisms of treatment resistance have gained particular attention. The cytokine interleukin 6 (IL-6) and its receptor weave through the hallmarks of malignant gliomas and may represent a key vulnerability to GB. Known for activating the STAT3 pathway in autocrine fashion, IL-6 is amplified in GB and has been recognized as a negative biomarker for GB prognosis, rendering it a putative target of novel GB therapies. While it has been recognized as a biologically active component of GB for three decades only with concurrent advances in understanding of complementary immunotherapy has the concept of targeting IL-6 for a human clinical trial gained scientific footing.
尽管胶质母细胞瘤（GB）患者的生存率前所未有，但这种侵袭性原发性脑癌在很大程度上仍是无法治愈的，其治疗耐药机制引起了特别关注。细胞因子白细胞介素 6（IL-6）及其受体贯穿恶性神经胶质瘤的特征，可能代表 GB 的一个关键脆弱性。IL-6 以自分泌方式激活 STAT3 通路而闻名，在 GB 中扩增，并被认为是 GB 预后的负生物标志物，使其成为新型 GB 治疗的潜在靶点。虽然三十年来人们一直认识到 IL-6 是 GB 的一种具有生物活性的成分，但随着对互补免疫疗法的理解的同步进展，针对 IL-6 进行人体临床试验的概念才获得了科学依据。
